Haisco Pharmaceutical Group Co Ltd
SZSE:002653
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
19.62
39.64
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Haisco Pharmaceutical Group Co Ltd
Haisco Pharmaceutical Group Co Ltd
Revenue
Haisco Pharmaceutical Group Co Ltd
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Haisco Pharmaceutical Group Co Ltd
SZSE:002653
|
Revenue
¥3.7B
|
CAGR 3-Years
9%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
13%
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Revenue
¥10.1B
|
CAGR 3-Years
5%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Revenue
¥10.9B
|
CAGR 3-Years
13%
|
CAGR 5-Years
15%
|
CAGR 10-Years
23%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Revenue
¥26B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
3%
|
CAGR 10-Years
14%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Revenue
¥39.3B
|
CAGR 3-Years
2%
|
CAGR 5-Years
7%
|
CAGR 10-Years
8%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Revenue
¥561.9m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Haisco Pharmaceutical Group Co Ltd
Glance View
Haisco Pharmaceutical Group Co., Ltd. is an embodiment of relentless ambition and strategic foresight in China's burgeoning pharmaceutical landscape. Founded in 2000, the company quickly carved a niche for itself by focusing on the research, development, production, and sale of a diverse array of pharmaceutical products. Haisco's journey is rooted in an ethos of innovation and quality, as it sought to establish itself as a leader in the creation of anesthetics and antipyretic analgesics, among other critical therapeutic products. The company's prowess in research and development is clearly evident in its extensive pipeline and its state-of-the-art manufacturing facilities, which meet international standards. These capabilities allow Haisco to capture significant market share domestically and extend its reach into international markets. Where Haisco truly shines is in its operational model and financial acumen, driving its revenue streams through both business-to-business (B2B) and business-to-consumer (B2C) channels. On the B2B side, Haisco partners with hospitals, clinics, and other healthcare institutions to supply essential medications, ensuring a steady stream of revenue from bulk orders. Meanwhile, its direct-to-consumer sales strategy leverages in-depth market research to target retail pharmacies and end customers with a razor-sharp focus on effectiveness and affordability. By maintaining a dual-channel approach that capitalizes on economies of scale and robust distribution networks, Haisco not only amplifies its market penetration but also fortifies its financial performance. The company's strategic investments in technology and its commitment to stringent quality controls underpin its success, fostering trust and loyalty among consumers and partners alike.
See Also
What is Haisco Pharmaceutical Group Co Ltd's Revenue?
Revenue
3.7B
CNY
Based on the financial report for Sep 30, 2024, Haisco Pharmaceutical Group Co Ltd's Revenue amounts to 3.7B CNY.
What is Haisco Pharmaceutical Group Co Ltd's Revenue growth rate?
Revenue CAGR 10Y
13%
Over the last year, the Revenue growth was 13%. The average annual Revenue growth rates for Haisco Pharmaceutical Group Co Ltd have been 9% over the past three years , -3% over the past five years , and 13% over the past ten years .
You don't have any saved screeners yet
